TY - JOUR
T1 - National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease
T2 - I. The 2020 Etiology and Prevention Working Group Report
AU - Williams, Kirsten M.
AU - Inamoto, Yoshihiro
AU - Im, Annie
AU - Hamilton, Betty
AU - Koreth, John
AU - Arora, Mukta
AU - Pusic, Iskra
AU - Mays, Jacqueline W.
AU - Carpenter, Paul A.
AU - Luznik, Leo
AU - Reddy, Pavan
AU - Ritz, Jerome
AU - Greinix, Hildegard
AU - Paczesny, Sophie
AU - Blazar, Bruce R.
AU - Pidala, Joseph
AU - Cutler, Corey
AU - Wolff, Daniel
AU - Schultz, Kirk R.
AU - Pavletic, Steven Z.
AU - Lee, Stephanie J.
AU - Martin, Paul J.
AU - Socie, Gerard
AU - Sarantopoulos, Stefanie
N1 - Publisher Copyright:
© 2021 The American Society for Transplantation and Cellular Therapy
PY - 2021/6
Y1 - 2021/6
N2 - Preventing chronic graft-versus-host disease (GVHD) remains challenging because the unique cellular and molecular pathways that incite chronic GVHD are poorly understood. One major point of intervention for potential prevention of chronic GVHD occurs at the time of transplantation when acute donor anti-recipient immune responses first set the events in motion that result in chronic GVHD. After transplantation, additional insults causing tissue injury can incite aberrant immune responses and loss of tolerance, further contributing to chronic GVHD. Points of intervention are actively being identified so that chronic GVHD initiation pathways can be targeted without affecting immune function. The major objective in the field is to continue basic studies and to translate what is learned about etiopathology to develop targeted prevention strategies that decrease the risk of morbid chronic GVHD without increasing the risks of cancer relapse or infection. Development of strategies to predict the risk of developing debilitating or deadly chronic GVHD is a high research priority. This working group recommends further interrogation into the mechanisms underpinning chronic GVHD development, and we highlight considerations for future trial design in prevention trials.
AB - Preventing chronic graft-versus-host disease (GVHD) remains challenging because the unique cellular and molecular pathways that incite chronic GVHD are poorly understood. One major point of intervention for potential prevention of chronic GVHD occurs at the time of transplantation when acute donor anti-recipient immune responses first set the events in motion that result in chronic GVHD. After transplantation, additional insults causing tissue injury can incite aberrant immune responses and loss of tolerance, further contributing to chronic GVHD. Points of intervention are actively being identified so that chronic GVHD initiation pathways can be targeted without affecting immune function. The major objective in the field is to continue basic studies and to translate what is learned about etiopathology to develop targeted prevention strategies that decrease the risk of morbid chronic GVHD without increasing the risks of cancer relapse or infection. Development of strategies to predict the risk of developing debilitating or deadly chronic GVHD is a high research priority. This working group recommends further interrogation into the mechanisms underpinning chronic GVHD development, and we highlight considerations for future trial design in prevention trials.
UR - http://www.scopus.com/inward/record.url?scp=85103581487&partnerID=8YFLogxK
U2 - 10.1016/j.jtct.2021.02.035
DO - 10.1016/j.jtct.2021.02.035
M3 - Review article
C2 - 33877965
AN - SCOPUS:85103581487
SN - 2666-6367
VL - 27
SP - 452
EP - 466
JO - Transplantation and Cellular Therapy
JF - Transplantation and Cellular Therapy
IS - 6
ER -